Get Cash Back and $0 Commissions
+ The Power of TradeStation
PRNewswire 3-Dec-2025 4:15 PM
GUANGZHOU, China, Dec. 3, 2025 /PRNewswire/ -- Pomdoctor Limited ("Pomdoctor" or the "Company") (NASDAQ:POM), a leading online medical services platform for chronic diseases in China, today announced its unaudited financial results for the six months ended June 30, 2025.
Mr. Zhenyang Shi, Chairman and Chief Executive Officer of Pomdoctor, commented: "The first half of fiscal year 2025 reflected our deliberate and disciplined efforts to balance business expansion with operational rigor. Despite a challenging macroeconomic environment and intensified market competition, we strived to strengthen our market coverage and penetration, while optimizing and diversifying our revenue streams through the vigorous promotion of our internet-hospital services and online sales. During the period, we continued to solidify our partner-doctor pool by offering higher service fees, and at the same time meaningfully enhanced our collaboration with pharmaceutical manufacturers to drive online sales and adapt to China's evolving healthcare landscape. These initiatives resulted in a 16.2% increase in net revenue, highlighted by growth of 83.2% in our online-pharmacy businesses.
At the same time, we maintained strict cost controls and operational discipline, sustaining a stable gross profit margin of 16.2%. Gross profit increased 16.3% year over year, despite higher sales and marketing expenses, a larger contribution from lower-margin pharmacy products, and continued investments in customer acquisition. We prioritized retaining doctor resources while prudently reducing advertising spending, reinforcing the foundation for sustainable growth under a stable pharmaceutical supply chain.
Notably, our successful initial public offering (IPO) in October provided us with additional capital resources and expanded opportunities for future growth, further enriching our strategic options and strengthening our execution capabilities. Looking ahead, we are confident in our ability to continue improving operational performance and creating long-term value for our shareholders."
First Half of Fiscal 2025 Financial Summary
Unaudited Financial Results for the First Half of Fiscal 2025
Financial Condition
Exchange Rate Information
This announcement contains translations of certain RMB amounts into U.S. dollars at a specified rate solely for the convenience of the reader. Unless otherwise noted, all translations from RMB to U.S. dollars are made at a rate of RMB7.1636 to US$1.00, the rate set forth in the H.10 statistical release of the U.S. Federal Reserve Board on June 30, 2025.
Recent Development
On October 9, 2025, the Company completed its initial public offering (the "Offering") of 5,000,004 American Depositary Shares ("ADSs") at a public offering price of US$4.00 per ADS. On October 10, 2025, the underwriter of the Offering fully exercised its over-allotment option to purchase an additional 750,000 American Depositary Shares of the Company at the public offering price of US$4.00 per share. The gross proceeds were US$23,000,016 from the Offering, before deducting underwriting discounts and commissions, and other expenses. The Company's ADSs began trading on the Nasdaq Global Market on October 8, 2025 under the ticker symbol "POM."
About POMDOCTOR LIMITED
POMDOCTOR LIMITED is a leading online medical services platform for chronic diseases in China, ranking sixth on China's Internet hospital market based on the number of contracted doctors in 2022, according to Frost & Sullivan. Focusing on chronic disease management and pharmaceutical services, the Company offers a one-stop platform for medical services, organically connecting patients with doctors and pharmaceutical products. The Company's operations primarily include Internet hospital and pharmaceutical supply chain, connecting users, pharmacies, suppliers, medical professionals, and other healthcare participants. Through this model, POMDOCTOR aims to enhance the efficiency and transparency of the healthcare value chain. The Company's mission is to provide effective prevention and treatment solutions to alleviate patients' sufferings from illnesses. Its vision is to become the most trustworthy medical and healthcare services platform. For more information, please visit the Company's website: http://ir.7shiliu.com.
Forward-Looking Statements
Certain statements in this announcement are forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company's current expectations and projections about future events that the Company believes may affect its financial condition, results of operations, business strategy and financial needs. Investors can find many (but not all) of these statements by the use of words such as "approximates," "believes," "hopes," "expects," "anticipates," "estimates," "projects," "intends," "plans," "will," "would," "should," "could," "may" or other similar expressions. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company's filings with the SEC.
For more information, please contact:
POMDOCTOR LIMITED
Investor Relations Department
Email: ir@7lk.com
Ascent Investor Relations LLC
Tina Xiao
Phone: +1-646-932-7242
Email: investors@ascent-ir.com
POMDOCTOR LIMITED UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS | ||||||||||||
December 31, | June 30, | June 30, | ||||||||||
RMB | RMB | US$ | ||||||||||
Assets | ||||||||||||
Current assets: | ||||||||||||
Cash and cash equivalents (including amounts of the consolidated VIEs of | 7,651,695 | 5,746,989 | 802,249 | |||||||||
Accounts receivable, net (including amounts of the consolidated VIEs of | 8,374,608 | 6,128,066 | 855,445 | |||||||||
Accounts receivable – a related party (including amounts of the | 424,259 | 584,802 | 81,635 | |||||||||
Amount due from related parties (including amounts of the consolidated | 5,632,987 | 7,418,671 | 1,035,607 | |||||||||
Inventories (including amounts of the consolidated VIEs of | 9,165,973 | 6,447,637 | 900,055 | |||||||||
Other receivables, net (including amounts of the consolidated VIEs of | 5,318,724 | 5,231,722 | 730,319 | |||||||||
Advances to suppliers (including amounts of the consolidated VIEs of | 929,167 | 2,921,966 | 407,891 | |||||||||
Total current assets | 37,497,413 | 34,479,853 | 4,813,201 | |||||||||
Non-current assets: | ||||||||||||
Property and equipment, net (including amounts of the consolidated VIEs | 461,362 | 394,107 | 55,015 | |||||||||
Other non-current assets (including amounts of the consolidated VIEs of | 831,132 | 1,307,832 | 182,566 | |||||||||
Deferred offering costs (including amounts of the consolidated VIEs of | 7,437,679 | 7,690,157 | 1,073,505 | |||||||||
Total non-current assets | 8,730,173 | 9,392,096 | 1,311,086 | |||||||||
Total assets | 46,227,586 | 43,871,949 | 6,124,287 | |||||||||
POMDOCTOR LIMITED UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS — (Continued) | ||||||||||||
December 31, | June 30, | June 30, | ||||||||||
RMB | RMB | US$ | ||||||||||
Liabilities | ||||||||||||
Current liabilities: | ||||||||||||
Accounts payable (including amounts of the consolidated VIEs of | 25,320,486 | 25,164,804 | 3,512,871 | |||||||||
Accounts payable – a related party (including amounts of the consolidated | 25,891 | 13,711 | 1,914 | |||||||||
Short-term bank loans (including amounts of the consolidated VIEs of | 34,958,333 | 34,708,333 | 4,845,096 | |||||||||
Long-term bank loans, current (including amounts of the consolidated | 300,000 | 2,400,000 | 335,027 | |||||||||
Long-term loans, current (including amounts of the consolidated VIEs of | 10,000,000 | 10,000,000 | 1,395,946 | |||||||||
Long-term loans from third parties, current (including amounts of the | 2,320,082 | 2,295,082 | 320,381 | |||||||||
Salary and welfare payable (including amounts of the consolidated VIEs | 15,375,537 | 15,543,259 | 2,169,755 | |||||||||
Advance from customers (including amounts of the consolidated VIEs of | 1,756,046 | 942,724 | 131,599 | |||||||||
Value added tax ("VAT") and other tax payable (including amounts of the | 815,462 | 998,295 | 139,357 | |||||||||
Other payables (including amounts of the consolidated VIEs of | 12,888,750 | 10,543,438 | 1,471,806 | |||||||||
Accrued liabilities (including amounts of the consolidated VIEs of | 9,712,966 | 11,564,144 | 1,614,292 | |||||||||
Short-term loans from third parties (including amounts of the consolidated | 11,551,614 | 7,194,342 | 1,004,291 | |||||||||
Loans from related parties, current (including amounts of the consolidated | 13,821,875 | 33,194,670 | 4,633,797 | |||||||||
Amount due to related parties (including amounts of the consolidated | 36,829,010 | 42,403,073 | 5,919,241 | |||||||||
POMDOCTOR LIMITED UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS — (Continued) | ||||||||||||
December 31, | June 30, | June 30, | ||||||||||
RMB | RMB | US$ | ||||||||||
Operating lease liabilities, current (including amounts of the | 1,388,863 | 1,790,319 | 249,919 | |||||||||
Other current liabilities (including amounts of the consolidated | 2,080,556 | 237,580 | 33,165 | |||||||||
Total current liabilities | 179,145,471 | 198,993,774 | 27,778,457 | |||||||||
Long-term bank loans, noncurrent (including amounts of the | 8,400,000 | 5,700,000 | 795,689 | |||||||||
Loans from related parties, noncurrent (including amounts of the | 356,690,859 | 356,390,859 | 49,750,246 | |||||||||
Operating lease liabilities, noncurrent (including amounts of the | 1,672,218 | 2,346,664 | 327,582 | |||||||||
Total non-current liabilities | 366,763,077 | 364,437,523 | 50,873,517 | |||||||||
Total liabilities | 545,908,548 | 563,431,297 | 78,651,974 | |||||||||
Commitments and contingencies | — | — | — | |||||||||
Mezzanine equity | ||||||||||||
Convertible redeemable preferred shares (US$0.0001 par value; | 1,595,051,558 | 1,642,498,390 | 229,283,934 | |||||||||
Redeemable non-controlling interests | 168,671,234 | 173,630,137 | 24,237,833 | |||||||||
Total mezzanine equity | 1,763,722,792 | 1,816,128,527 | 253,521,767 | |||||||||
Equity (deficit) | ||||||||||||
Class A ordinary shares (US$0.0001 par value; 485,360,730 | 2,988 | 2,988 | 417 | |||||||||
Class B Ordinary shares (US$0.0001 par value; 2,042,042 shares | 1,408 | 1,408 | 197 | |||||||||
Subscription receivable | (1,608) | (1,608) | (224) | |||||||||
Accumulated deficit | (2,263,419,477) | (2,335,709,744) | (326,052,508) | |||||||||
Accumulated other comprehensive (loss) income | (5,231) | 1,875 | 262 | |||||||||
Total Pomdoctor Limited's shareholders' deficit | (2,263,421,920) | (2,335,705,081) | (326,051,856) | |||||||||
Noncontrolling interests | 18,166 | 17,206 | 2,402 | |||||||||
Total deficit | (2,263,403,754) | (2,335,687,875) | (326,049,454) | |||||||||
Total liabilities, mezzanine equity and deficit | 46,227,586 | 43,871,949 | 6,124,287 | |||||||||
POMDOCTOR LIMITED UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS | ||||||||||||
For Six Months Ended June 30, | ||||||||||||
2024 | 2025 | 2025 | ||||||||||
RMB | RMB | US$ | ||||||||||
Net revenues – third parties | 149,266,587 | 174,283,295 | 24,329,010 | |||||||||
Net revenues – a related party | 897,822 | 186,556 | 26,042 | |||||||||
Net revenues | 150,164,409 | 174,469,851 | 24,355,052 | |||||||||
Cost of revenues | 125,823,734 | 146,152,450 | 20,402,095 | |||||||||
Gross profit | 24,340,675 | 28,317,401 | 3,952,957 | |||||||||
Operating expenses: | ||||||||||||
Sales and marketing expenses | 24,884,898 | 27,761,736 | 3,875,389 | |||||||||
General and administrative expenses | 6,835,897 | 10,494,487 | 1,464,974 | |||||||||
Research and development expenses | 1,507,847 | 1,479,909 | 206,587 | |||||||||
Impairment loss on long-lived assets | 17,861 | 2,041,299 | 284,954 | |||||||||
Total operating expenses | 33,246,503 | 41,777,431 | 5,831,904 | |||||||||
Loss from operations | (8,905,828) | (13,460,030) | (1,878,947) | |||||||||
Other income (expenses): | ||||||||||||
Other income | 1,078,270 | 28,027 | 3,912 | |||||||||
Other expense | (33,681) | (130,291) | (18,188) | |||||||||
Interest expense | (6,179,172) | (6,471,198) | (903,344) | |||||||||
Government grants | 13,858 | 148,000 | 20,660 | |||||||||
Total other expense, net | (5,120,725) | (6,425,462) | (896,960) | |||||||||
Loss before income tax | (14,026,553) | (19,885,492) | (2,775,907) | |||||||||
Income tax expense | — | — | — | |||||||||
Net loss | (14,026,553) | (19,885,492) | (2,775,907) | |||||||||
Accretion to redemption value of mezzanine equity | (52,695,272) | (52,405,735) | (7,315,559) | |||||||||
Less: Net income (loss) attributable to noncontrolling interests | 27,639 | (960) | (134) | |||||||||
Net loss attributable to the Pomdoctor Limited's ordinary | (66,749,464) | (72,290,267) | (10,091,332) | |||||||||
Net loss | (14,026,553) | (19,885,492) | (2,775,907) | |||||||||
Other comprehensive (loss) income: | ||||||||||||
Total other comprehensive (loss) income | (3,970) | 7,106 | 992 | |||||||||
Total comprehensive loss | (14,030,523) | (19,878,386) | (2,774,915) | |||||||||
Accretion to redemption value of mezzanine equity | (52,695,272) | (52,405,735) | (7,315,559) | |||||||||
Less: comprehensive income (loss) attributable to noncontrolling | 27,639 | (960) | (134) | |||||||||
Comprehensive loss attributable to the Pomdoctor Limited's | (66,753,434) | (72,283,161) | (10,090,340) | |||||||||
Loss per share | ||||||||||||
Basic and diluted | (10.58) | (11.45) | (1.60) | |||||||||
Weighted average number of ordinary shares outstanding* | ||||||||||||
Basic and diluted | 6,310,198 | 6,310,198 | 6,310,198 | |||||||||
* Ordinary shares and share data have been retroactively restated to give effect to the nominal share issuance for | ||||||||||||
POMDOCTOR LIMITED UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS | ||||||||||||
For Six Months Ended June 30, | ||||||||||||
2024 | 2025 | 2025 | ||||||||||
RMB | RMB | US$ | ||||||||||
Net cash used in operating activities | (10,631,121) | (14,987,658) | (2,092,195) | |||||||||
Cash flows from investing activities: | ||||||||||||
Payment for purchase of property and equipment | (17,862) | (2,200) | (307) | |||||||||
Payment for long-term investment | — | (510,000) | (71,193) | |||||||||
Net cash used in investing activities | (17,862) | (512,200) | (71,500) | |||||||||
Cash flows from financing activities: | ||||||||||||
Loans from related parties | 11,219,986 | 24,750,310 | 3,455,010 | |||||||||
Repayment to related parties | (14,436,941) | (5,677,514) | (792,550) | |||||||||
Proceeds from short-term bank loans | 37,000,000 | 29,000,000 | 4,048,244 | |||||||||
Repayment of short-term bank loans | (19,300,000) | (29,250,000) | (4,083,143) | |||||||||
Repayment of long-term bank loans | (54,628) | (600,000) | (83,757) | |||||||||
Loans from third parties | 8,759,366 | 1,600,000 | 223,351 | |||||||||
Repayment to third parties | (4,968,912) | (5,982,272) | (835,093) | |||||||||
Payment for deferred offering cost | (1,656,745) | (252,478) | (35,245) | |||||||||
Net cash provided by financing activities | 16,562,126 | 13,588,046 | 1,896,817 | |||||||||
Effect of exchange rate changes | (3,970) | 7,106 | 992 | |||||||||
Net increase (decrease) in cash and cash equivalents and restricted | 5,909,173 | (1,904,706) | (265,886) | |||||||||
Cash and cash equivalents and restricted cash at beginning of the | 6,805,099 | 7,651,695 | 1,068,135 | |||||||||
POMDOCTOR LIMITED UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS — (Continued) | ||||||||||||
For Six Months Ended June 30, | ||||||||||||
2024 | 2025 | 2025 | ||||||||||
RMB | RMB | US$ | ||||||||||
Including: | ||||||||||||
Cash and cash equivalents at beginning of the period | 6,717,031 | 7,651,695 | 1,068,135 | |||||||||
Restricted cash at beginning of the period | 88,068 | — | — | |||||||||
Cash and cash equivalents and restricted cash at end of the period | 12,714,272 | 5,746,989 | 802,249 | |||||||||
Including: | ||||||||||||
Cash and cash equivalents at end of the period | 12,714,272 | 5,746,989 | 802,249 | |||||||||
Supplemental disclosures of cash flows information: | ||||||||||||
Cash paid for interest expense | 1,130,609 | 2,382,125 | 332,532 | |||||||||
Supplemental disclosure of noncash investing and financing activities: | ||||||||||||
Operating lease right-of-use assets obtained in exchange for new operating | — | 2,039,099 | 284,647 | |||||||||
View original content:https://www.prnewswire.com/news-releases/pomdoctor-limited-announces-first-half-of-fiscal-2025-unaudited-financial-results-302632067.html
SOURCE POMDOCTOR LIMITED